Carcinoma, Squamous Cell Clinical Trial
— DEMOOfficial title:
Tobacco and Alcohol Influence on Oncogenic Drivers and Somatic Evolution in the Oral Mucosa
Head and neck cancers represent more than 500,000 cases per year worldwide, and often involve post-treatment relapse. The oral cavity is the most frequent site, but early disease stages are still insufficiently characterised and poorly detected. The study's aim is to better understand the oral mucosa somatic evolution, and how it can give rise to oral squamous cell carcinoma (OSCC). This is a multi-centric, descriptive, non-interventional cohort in healthy adult subjects. The aim of the study is to detect the presence of OSCC driver gene mutations in healthy subjects' oral mucosa, quantify whether they provide cells with a selective advantage, and study the impact of tobacco and alcohol consumption on the mutational load. This study will not allow to identify potential malignant cells, and will be usable for diagnostic purposes.
Status | Not yet recruiting |
Enrollment | 100 |
Est. completion date | November 15, 2024 |
Est. primary completion date | November 15, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Man or woman aged 18 or more. - Subject coming to odontology practice for routine visit. - Subject having accepted to participate to the research by oral non-opposition - Subject having given additional written consent for genetic studies. - Smoking group criterion: subjects having smoked 100+ cigarettes/joints during their life. Exclusion Criteria: - Personal history of cancer, whichever the type. - Treatment with anticoagulants or platelet aggregation inhibitors. - Bilateral lesions of the inner cheek preventing painless biological sample collection. - Subject under under guardians or curators - Pregnancy or breastfeeding - Cannabis usage |
Country | Name | City | State |
---|---|---|---|
France | Cabinet Libéral Picquendar | Bougival | |
France | Cabinet Libéral Balayre | Chassieu | |
France | Cabinet Libéral Debeauvais | Châtillon-Coligny | |
France | Cabinet Libéral Finet | Fontaine-lès-Dijon | |
France | Cabinet Libéral Jaeggy | Haguenau | |
France | Cabinet Libéral Grammatica | Lyon | |
France | Centre de Consultations et de Traitements Dentaires HCL | Lyon | |
France | Unité de chirurgie et médecine orales (UCMO) - HCL - Hôpital Edouard Herriot- Pavillon R | Lyon | |
France | Cabinet Libéral Cougot | Meudon | |
France | Cabinet Libéral Calvo | Quint-Fonsegrives | |
France | Cabinet Libéral Glomet | Saumur | |
France | Cabinet Libéral Dutour | Theix | |
France | Cabinet Libéral Masri | Vandœuvre-lès-Nancy | |
France | Cabinet Libéral Bondil | Villefranche-sur-Saône | |
France | Cabinet Libéral Janisset-Masse | Villiers-sur-Marne |
Lead Sponsor | Collaborator |
---|---|
Hospices Civils de Lyon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prevalence of non-synonymous OSCC driver mutations in the healthy mucosa of smokers | Difference in mean number of non-synonymous mutations found in OSCC driver genes between smokers and non-smokers. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02743832 -
A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.
|
N/A | |
Active, not recruiting |
NCT02229656 -
Olaparib and Radiotherapy in Head and Neck Cancer
|
Phase 1 | |
Completed |
NCT00389727 -
Simultaneous Integrated Boost (SIB)- IMRT
|
Phase 2 | |
Recruiting |
NCT02328391 -
STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE
|
N/A | |
Completed |
NCT00875381 -
Analysis of Melanocytes (Pigment Cells) in Sun-Exposed Skin
|
N/A | |
Completed |
NCT00534950 -
Randomized Multicenter Study of 5 vs 6 Weekly Fraction of RT in the Treatment of SCC of the Head and Neck
|
N/A | |
Terminated |
NCT00073450 -
Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)
|
Phase 2 | |
Terminated |
NCT01441128 -
-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05970497 -
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT01362127 -
Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia
|
Phase 2 | |
Completed |
NCT00240682 -
Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR
|
Phase 2 | |
Terminated |
NCT02254044 -
Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus
|
Phase 1 | |
Active, not recruiting |
NCT00829192 -
Phase II AK Study in Organ Transplant Patients
|
Phase 2 | |
Completed |
NCT00313027 -
Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation
|
N/A | |
Completed |
NCT00539630 -
TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN
|
Phase 3 | |
Recruiting |
NCT04564989 -
Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
|
||
Recruiting |
NCT04481256 -
TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY
|
N/A | |
Active, not recruiting |
NCT02664935 -
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT02438995 -
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
|
Phase 1 | |
Terminated |
NCT00673049 -
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer
|
Phase 3 |